Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Takeda Global Research & Development Center, Inc. |
---|---|
Information provided by: | Takeda Global Research & Development Center, Inc. |
ClinicalTrials.gov Identifier: | NCT00671398 |
This purpose of this study is to evaluate the safety and efficacy of TAK-375 in healthy subjects within a sleep lab.
Condition | Intervention | Phase |
---|---|---|
Transient Insomnia |
Drug: TAK-375 Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Single-Dose Study of TAK-375 in Healthy Adult Volunteers in a Sleep Lab Model of Transient Insomnia |
Enrollment: | 289 |
Study Start Date: | December 2002 |
Study Completion Date: | May 2003 |
Primary Completion Date: | May 2003 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1.: Experimental |
Drug: TAK-375
TAK-375 8 mg, tablets, orally for one night only.
|
2.: Experimental |
Drug: TAK-375
TAK-375 16 mg, tablets, orally for one night only
|
3.: Placebo Comparator |
Drug: Placebo
TAK-375 placebo-matching tablets, orally for one night only
|
Insomnia is characterized by difficulties initiating and maintaining sleep, or of non-restorative and non-refreshing sleep. Transient insomnia affects approximately one-third to one-half of the US population, based on the results of 2 surveys of representative samples of the adult US population conducted by the Gallup Organization in which respondents were asked if they had "ever had difficulty sleeping." Based on reports of "regular" or "frequent" sleep difficulty, results from the same studies suggest that approximately one-tenth of the US population experiences chronic insomnia. The ideal treatment for insomnia would reduce the latency to onset of sleep and increase total sleep time, without a negative impact on sleep architecture and without safety concerns or next-day effects.
TAK-375 is a selective melatonin-1 receptor agonist under global development by Takeda Chemical Industries, Ltd., for the treatment of transient and chronic insomnia and for the treatment of Circadian Rhythm Sleep Disorders.
This study is being conducted to evaluate the safety and efficacy of a single dose of TAK-375 in normal healthy subjects in a sleep lab model of transient insomnia. Participation is this study is anticipated to be about 3 weeks.
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria
Exclusion Criteria:
Any additional condition(s) that in the investigator's opinion would
Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication, including:
United States, California | |
San Diego, California, United States | |
Palm Springs, California, United States | |
United States, Florida | |
Miami, Florida, United States | |
Pembroke Pines, Florida, United States | |
United States, Georgia | |
Atlanta, Georgia, United States | |
United States, Kansas | |
Overland Park, Kansas, United States | |
United States, New York | |
New York, New York, United States | |
Rochester, New York, United States | |
United States, Ohio | |
Cincinnati, Ohio, United States | |
Dublin, Ohio, United States | |
United States, South Carolina | |
Columbia, South Carolina, United States | |
United States, Texas | |
Houston, Texas, United States |
Study Director: | VP Clinical Science | Takeda Global Research & Development Center, Inc. |
Responsible Party: | Takeda Global Research & Development Center, Inc. ( Sr. VP, Clinical Science ) |
Study ID Numbers: | 01-02-TL-375-023 |
Study First Received: | May 1, 2008 |
Last Updated: | February 26, 2009 |
ClinicalTrials.gov Identifier: | NCT00671398 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Insomnia Sleep Disorder Drug Therapy |
Sleep Initiation and Maintenance Disorders Mental Disorders Dyssomnias |
Sleep Disorders Healthy Sleep Disorders, Intrinsic |
Sleep Initiation and Maintenance Disorders Mental Disorders Nervous System Diseases |
Sleep Disorders Dyssomnias Sleep Disorders, Intrinsic |